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Summary: We report here on an evaluation of the enzyme-multiplied immunoassay technique (EMIT™) from
Syva for cyclosporin A (ciclosporin, INN) concentration measurements in whole blood. The assay incorporates
a monoclonal antibody for specific determination of ciclosporin. Measurements by EMIT were performed on
the Cobas Mira-S from Roche. A total of 197 blood specimens from heart- (n = 74), kidney- (n = 62) and
liver- (n = 61) transplant recipients were analyzed. EMIT values correlated well with those obtained by
HPLC, as well as with those obtained by a selective radioimmunoassay (INCStar). Ciclosporin concentrations
determined by EMIT (y) agreed very well with those by RIA, and averaged 8% higher than those by HPLC
(x) [n = 197, χ = 143 μg/l, y = 155 μg/l, y = 1.09x - 0.6, r = 0.969]. Within-series and between-days CVs
ranged from 4.6% to 7.3% for ciclosporin concentrations > 100 μg/l, and from 5.5% to 10.5% for ciclosporin
concentrations between 69.5 μg/l and 100μg/l. The within-series CV for a concentration of 45.5 μg/l was
14.8%. Calibration employing a 2-point mode instead of a continuous mode of UV-signal evaluation improved
the precision of the EMIT assay at low ciclosporin concentrations. Sample pretreatment required thorough
and skilful performance to avoid false positive ciclosporin measurements. We conclude that the EMIT assay
is specific, and rapid to perform. It can be effectively used in the monitoring of ciclosporin concentrations in
whole blood.
Introduction
Routine monitoring of the cyclosporin (ciclosporin,
INN) concentration in whole blood has been recom-
mended for guiding individualized adjustment of the
ciclosporin dosage for adequate immunosuppression
and to reduce toxicity (1 — 3). Different immunoassays
and high performance liquid chromatography
(HPLC) have been used for monitoring ciclosporin
concentrations in whole blood. Proficiency tests, ex-
ternal surveys, and method comparisons have shown
that the variety of the immunoassays employed, as
well as the different HPLC methods, led to insufficient
comparability between laboratories (4 — 6). HPLC is
a method that enables in principle selective separation
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of ciclosporin from its metabolites (7). Nonetheless,
despite the superior specificity of ciclosporin measure-
ments by HPLC there are analytical reasons that
argue against this technique for regular routine mon-
itoring. The complexity of HPLC methods for ciclo-
sporin analyses in blood requires the skill of a well-
trained operator to avoid poor reproducibility of the
results obtained (8). Furthermore, the long turna-
round time due to sample pretreatment and chro-
matography is unfavourable for regular ciclosporin
monitoring with larger series of samples. The devel-
opment of selective immunoassays for determination
of the parent drug is complicated by the extensive
metabolism of ciclosporin. The availability of radio-
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immunoassays (RIA) involving a selective mono-
clonal antibody has improved selective ciclosporin
analysis. Cross-reactivities with certain ciclosporin
metabolites are minor even when samples contain
large amounts of ciclosporin metabolites (9, 10). The
introduction of a fluorescence polarization immuno-
assay (FPIA) employing a monoclonal antibody has
made accessible relatively specific ciclosporin mea-
surements by non-isotopic immunoassay technology
(11). The major advantage of this semi-automated
procedure, run on the TDx (Abbott), is an easy-to-
perform sample pretreatment, and improved manage-
ment of large numbers of samples. The reproducibility
of ciclosporin determinations is good. Recently, a
specific EMIT for ciclosporin analysis in whole blood
using semi-automated feasibility has been introduced
by Syva Company (Palo Alto, CA). We report here
our evaluation of this assay, which was run on the
Cobas Mira-S (Roche). Method comparisons were
performed using HPLC and the RIA from INCStar
which has been the in-house routine method for ci-
closporin monitoring. The first goal was to evaluate
the specificity of the EMIT by correlation studies with
specimens from transplant recipients. Furthermore,
we investigated modifications of the sample pretreat-
ment and the instrument settings in order to improve




The EMIT™ ciclosporin assay kit was provided by Syva Co.
(Darmstadt, Germany). Reagent A contains NAD+, the sub-
strate glucose-6-phosphate, and a monoclonal antibody selec-
tive for ciclosporin. Reagent B contains ciclosporin linked to
glucose-6-phosphate dehydrogenase enzyme (EC 1.1.1.49), and
Tris buffer. The test kit is complemented by a diluent (consisting
of Tris buffer, surfactant, and preservatives), and six whole-
blood calibrators (ciclosporin concentrations: 0, 50, 100, 200,
350, and 500 μg/l). Methanol p. a. grade was purchased from
Merck (Darmstadt, Germany). At the outset of our study,
sample pretreatment was performed according to Syva's origi-
nal assay protocol. The original protocol prescribes pipetting
of 100 μΐ whole blood from patient specimens, calibrators, and
control materials into round bottom polypropylene tubes. A
pipettor operating with positive displacement and with a glass
capillary (Transferpettor, Rudolf Brand GmbH, Wertheim, Ger-
many) was used for the pipetting of whole blood. Proteins were
precipitated by the addition of 200 μΐ methanol followed by
1 -2 min of incubation. Vigorous centrifugation (11 000 min"1;
10 500 g) for 5 min was performed using a desk centrifuge from
Abbott. We modified the sample pretreatment after it became
obvious that the recommended procedure was inappropriate
for separating the supernatant easily from floating particles.
One modification was to transfer the supernatant after centri-
fugation into a clean conical polypropylene tube and repeat the
centrifugation. The other, less labour intensive modification,
recommended later in a revised Syva protocol, doubled the
volume of the sample (to 200 μΐ) and that of the methanol (to
400 μΐ), but with only one centrifugation step. An aliquot (100
μΐ) of the supernatant was diluted with 200 μΐ diluent using a
pipetter/dilutor from Syva Co. The mixture was transferred
into polypropylene sample cups, and the EMIT assay was
performed on a Cobas Mira^S analyzer (Roche Analytical In-
struments; Basel, Switzerland). During the study the instrument
was operated exclusively for ciclosporin analyses. The enzyme
activity was monitored in a continuous mode according to
Syva's prescription for the assay. The instrument was pro-
grammed to monitor the absorbance of N ADH at 340 nm for
350 seconds, thereby recording 15 absorbance measurements at
intervals of 25 s. The calculated mean absorbance difference,
to the ciclosporin related concentration, was the average of
four absorbance differences measured between points 11 and
15 (fig. 1). Each run was recalibrated. We also investigated a
modification of the measuring design employing a 2-point mode
instead of measurements in the original continuous mode. The
measuring time was prolonged to 400 s, and the absorbance
difference was monitored between measuring points 13 and 17
(fig. 1). The lower limit of the measuring range for ciclosporin
concentrations was set at 50 μg/l according to Syva's recom-
mendation, even though lower ciclosporin concentrations were
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Fig. 1. Two measuring designs for Ν ADH absorbance moni-
toring at 340 nm: a continuous mode (r~) employing a
measuring time of four intervals of 25 s, and a 2-point
mode (—) employing an interval of 100 s.
RIA routine method
The RIA (CYCLO-Trac® SP-whole-blood radioimmunoassay,
INCStar Corp., Stillwater, MN) was performed according to
the manufacturer's instructions. Calibrators were prepared in-
house employing whole blood from donors, which was supple-
mented with ciclosporin standard material in methanol solution
(provided by Sandoz, Basel, Switzerland).
HPLC method
High performance liquid chromatpgraphy was performed on
an HP-1090 instrument (Hewlett Packard, Waldbronn, Ger-
many). Sample pretreatment was performed by several liquid-
liquid extraction procedures prior to HPLC analysis. Sequential
reversed-phase chromatography was run with coupled columns:
, Column-1 contained in-house filled packing material C6 (Spher-
isorb; Phase Separations Inc., Norwalk, CT), and colutnn-2
contained Cw (Hypersil-ODS; Shandon Scientific Ltd., Chesh-
ire, U. K.). We eluted ciclosporin from the columns by use of a
gradient consisting of water, methanol and acetonitrii. Calibra-
tors were prepared in-house as previously described (6).
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 6
Schumann et al.: Evaluation of the EMIT ciclosporin assay 383
Control specimens
Three whole blood ciclosporin controls (levels 1—3) were pur-
chased from Bio-Rad (M nchen, Germany). Different control
materials prepared in-house had ciclosporin concentrations of
50,100, and 250 μ§/1. One set of control specimens was provided
by Syva Co. The set consisted of 10 specimens supplemented
with ciclosporin at concentrations between 60 μ§/1 and 425 μ§/1.
This set was used for analytical recovery experiments of ciclo-
sporin. The limited amount of sample volume provided allowed
duplicate measurements with EMIT, but only single analysis
with HPLC.
Clinical specimens
Blood specimens were collected from patients during the post-
transplant course with ciclosporin immunosuppression. Trans-
plant recipients mostly received ciclosporin in combination with
other immunosuppressants (12). All specimens were drawn 12 h
after the last administration of a ciclosporin dose. Whole blood
was collected into lubes coated with the anticoagulant ethyl-
enediaminetetraacetic acid (EDTA). The first analysis was per-
formed by RIA in the course of the regular ciclosporin moni-
toring. Analyses of the ciclosporin concentration by EMIT and
by HPLC were performed not later than 5 days after collection
of these specimens. The specimens had been stored at 4 °C. At
most four specimens from the same patient were employed in
each method comparison. The specimens were collected on
different days.
Study design of method comparisons
We performed two method comparison studies with specimens
from transplant recipients. Study I followed exactly the Syva
assay protocol. We employed the sample pretreatment with 100
μΐ sample volume, and single centrifugation. Calibration and
ciclosporin analysis were performed by signal evaluation em-
ploying the continuous mode. Study I included 208 specimens
from 158 different patients. The aim of this study was the
evaluation of the specificity of EMIT in comparison both with
HPLC, and with specific RIA. Therefore, the selection of pa-
tient specimens was such that samples with relatively low ci-
closporin metabolite concentrations (renal, heart), and those
with larger metabolite concentrations (heart, liver) were chosen.
The aim of Study II was not primarily the evaluation of the
specificity of EMIT; rather, we assessed the analytical perform-
ance of EMIT using two modifications of the assay. One mod-
ification of EMIT employed a small sample volume (100 μΐ),
two centrifugation steps, and the continuous mode for signal
evaluation (1EMIT). The second modification of the assay was
performed with a 200 μΐ sample volume, one centrifugation
step, and measurements by the described 2-point mode
^EMIT). Method comparisons in Study II were performed
with 102 blood specimens obtained from 72 different renal
transplant paediatric out-patients. Comparisons were per-
formed with RIA, but not with HPLC. The comparisons EMIT
versus RIA should provide sufficient information about the
analytical performance of EMIT.
The method comparisons in Study I and Study II were statis-
tically evaluated by standardized principal component analysis
(13), and the paired Student's t-test.
Results
Measuring design
The non-linear calibration curve of the EMIT had
very low slopes on use of the continuous mode. The
greatest recorded difference in absorbance range was
less than 0.01 absorbance units per 25 s for the ci-
closporin concentration of calibrator 6 (500 μg/l) at
the upper end of the measuring range. Although ab-
sorbance differences of the ciclosporin measurements
were averaged over readings of four consecutive 25 s
intervals, random variation was relatively large. This
observation was not unexpected, considering the
specified reproducibility of 0.0009 absorbance units
of the Cobas Mira-S instrument. The absorbance
differences were greater, and the calibration curve was
steeper, employing the 2-point calibration mode as
described above. Statistical calculations revealed that
Tab.l. Study of the imprecision of the EMIT ciclosporin assay



























































Single centrifugation, continuous mode
Double centrifugation, 2-point mode
Double centrifugation, 2-point mode
Single centrifugation, continuous mode
Double centrifugation, 2-point mode
Single centrifugation, continuous mode
Double centrifugation, 2-point mode
Single centrifugation, continuous mode
Single centrifugation, continuous mode
Single centrifugation, continuous mode
Single centrifugation, continuous mode
Single centrifugation, continuous mode
Single centrifugation, continuous mode
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the single but 4-fold higher signal obtained by the 2-
point mode, instead of the averaged but much smaller
absorbance difference obtained by the continuous
mode, should improve the precision of the assay at
low ciclosporin concentrations.
Study of the imprecision
of the EMIT™ ciclosporin assay
The within-series imprecision was investigated using
two different analytical designs. One design employed
single centrifugation during sample pretreatment, and
recording the NADH absorbance by the continuous
mode, as recommended by Syva. The alternative de-
sign employed double centrifugation, and a 2-point
mode for the NADH absorbance recording. At ci-
closporin concentrations of 101 μg/l up to 371 μg/l
the coefficients of variation (CVs) within-series ranged
between 6.6% and 4.6% regardless of the employed
sample pretreatment mode and the UV-signal evalu-
ation (tab. 1). We observed a CV of 8% for a ciclo-
sporin concentration of 69.5 μg/l (LEVEL1) using the
continuous mode. However, analyses of this control
specimen utilizing the 2-point measurement design
and two centrifugation steps determined a mean ciclo-
sporin concentration of 73.7 μg/l and a CV of 5.5%.
Evaluation of the between-days imprecision strictly
followed the initial Syva protocol. At ciclosporin con-
centrations between 92.6 μg/l and 340 μg/l the CVs
were around 7% (tab. 1). At ciclosporin concentra-
tions between 75.9 μg/l and 45.5 μg/l the CVs were
between 10.5% and 14.8%.
EMIT calibrator cross-check, and analytical
recovery
The six EMIT calibrators were cross-checked by
EMIT and by HPLC on three days during the study
(tab. 2). The employed sample pretreatment and the
measuring design for EMIT were performed accord-
ing to the original Syva assay prescription. All cali-
brators were assayed in duplicate both with regard to
the sample pretreatment, and to the measuring pro-
cedure. We observed satisfactory mean analytical re-
coveries between 88% and 112% with EMIT, except
with calibrator C 50 on day-II where the analytical
recovery was 124%. Multiple analysis by HPLC was
not performed due to the limited volume of the speci-
mens. The analytical recoveries obtained by the
HPLC method ranged between 83% and 113%, ex-
cept for one result which was 124% (C 350; day H),
Regarding only single measurements per day the in-
accuracy of HPLC was acceptable. The cross-check
at all revealed no systematic calibration error in either
of the two assays.
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Analytical recovery of ciclosporin in supple-
mented whole-blood samples
Nine specimens provided by Syva Co. had ciclosporin
target concentrations between 60 μ§/1 and 425 μ§/1,
one specimen was a blank (tab. 3). The employed
sample pretreatment and the measuring design for
EMIT were performed according to the original Syva
assay prescription. Specimens were analyzed on two
days by EMIT, but only once by HPLC due to the
limited amount of specimen available. Determinations
by EMIT revealed a mean recovery of 97% (range:
86-109%) on day I, and 101% (range: 93-113%)
on day ΪΙ. The analytical recovery obtained by HPLC
ranged from 97% to 113% (mean: 103%).
Method comparisons of Study I
Eleven of the 208 results of Study I samples were
classified as outliers as explained below. Therefore
only 197 specimens from kidney- (n = 62), heart-
Tab. 3. Analytical recovery of ciclosporin in supplemented whole blood samples























































































Tab. 4a. Comparisons of the results obtained from whole blood samples from 197 transplant recipients
Group Regression equation8
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Tab. 4b. Comparisons of the results obtained from whole blood samples from 102 paediatric transplant recipients
Group Regression equation*





































a Standardized principal component analysis.
btC*d Significance of the bias χ — y by paired t-test: bhighly significant (p < 0.001), Significant (P < 0.05), dnot significant
(P > 0.05).
'EMIT: pretreatment with 100 μΐ sample volume, double centrifugation, and continuous calibration mode.
2EM1T: pretreatment with 200 μΐ sample volume, single centrifugation, and 2-point calibration mode.
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(n = 74), and liver- (n = 61) transplant recipients
were evaluated statistically in this study. Good cor-
relations between EMIT, RIA, and HPLC .were ob-
served with the ciclosporin results of these remaining
197 samples (tab. 4a). Mean ciclosporin concentra-
tions of EMIT and RIA were 5-10% higher than
HPLC results. Ciclosporin measurements by EMIT
and RIA did not differ significantly except for the
renal transplant group (P < 0.05). We observed
highly significantly differing results (P < 0.001) be-
tween ciclosporin determinations obtained by HPLC
and by EMIT, and also highly significantly differing
results between measurements obtained by HPLC and
by RIA with one exception (renal transplant:
P > 0.05). Ten measurements by EMIT and one by
RIA were repeated, because the initial determinations
in the excluded eleven specimens were suspected to
be wrong. The mean of the residuals (y · x) of the 10
outlying EMIT results was 73.7 μ§/1 (range: + 53.0
μg/l to +171 μg/l), while the mean of the residuals
of ciclosporin determinations after repeated analysis
by EMIT was 10.6 μg/l (rang^: -3.0 μg/l to + 49
μg/l). The residual of the only outlying RIA result
was 112 μg/l, and that of the repeated analysis was
14 μg/l. We decided to exclude the clarified outliers
from the statistical evaluation of the correlation study,
because the reason for the falsely elevated results
could not have been non-specificity. Despite the de-
cision to consider these results outliers the corre-
sponding data points are depicted in figure 2 by extra
symbols.
Method comparisons of Study II
The method comparison 'EMIT versus 2EMIT em-
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Fig. 2. Study I correlations with 208 ciclosporin concentration
measurements in whole blood, and the lines of identity
(x = y):
a) EMIT vs HPLC,
b) selective RIA vs HPLC,
c) EMIT vs selective RIA.
Ten results by EMIT (o), and one result by RIA (V)
were classified as outliers. The residuals of these outliers
exceeded the corresponding sy.x 5-fold to 15-fold. The
data points from repeated analyses were not depicted
in the plots. Neither the primary results nor the results
obtained by repeated analysis were included in the sta^
tistical evaluation of the method comparisons, although
the latter fit well into the corresponding correlations.
Ciclosporin (RIA) [μς/Ι]
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Fig. 3. Study II correlation with 102 ciclosporin concentration
measurements in whole blood determined by 1EMIT
versus selective RIA, and the line of identity (x = y).
The correlation is in good agreement with the corre-
sponding correlation of Study I. However, no outliers
were observed in Study II with a modified sample pre-
treatment.
excellent agreement of the obtained ciclosporin con-
! centration measurements (tab. 4b). We observed out-
« Hers neither by sample pretreatment with double cen-
1 trifugation (ΈΜΙΤ) nor by sample pretreatment with
a double sample volume and only single centrifuga-
tion ^EMIT). The two different modes of evaluation
of the UV-signals did not cause a significant bias. The
correlation studies 'EMIT versus RIA, and 2EMIT
versus RIA showed good agreement and had no sig-
nificant biases (tab. 4b). The plotted ciclosporin con-
centrations in figure 3 and the statistical data in table
4a/4b revealed that the correlation between the mod-
ified EMIT assay and RIA was in good agreement
with the results of the corresponding correlation be-
tween the original EMIT and RIA (fig. 2).
Discussion
We evaluated the analytical performance of the EMIT
for ciclosporin determinations in whole blood. Our
method comparison of EMIT versus specific HPLC
revealed a significant but small positive bias. The
ciclosporin measurements by EMIT averaged 8%
higher than those obtained by HPLC. EMIT and RIA
agreed very well. Our check of EMIT calibrators
revealed a satisfactory agreement between EMIT and
HPLC. The data suggested that EMIT appeared to
be affected by only minor cross-reactivities of certain
ciclosporin metabolites to the same degree as was
observed with the selective RIA. This non-specificity
of ciclosporin measurements is irrelevant in monitor-
ing transplant patients, and will not influence clinical
decisions. Three published studies also revealed sat-
isfactory comparability between ciclosporin measure-
ments by EMIT versus HPLC (14-16). In another
study the results obtained by EMIT differed by about
30% from HPLC (17). In this publication the results
of the cross-check of EMIT calibrators, and the an-
alytical recoveries in ten specimens provided by Syva
were comparable to the results of our study. However,
the standard error of estimate obtained from method
comparisons with samples from patients was 34.9 μg/l.
We observed a standard error of estimate of 11.0 μg/l
in our corresponding method comparison with com-
parable mean ciclosporin concentrations, but ten out-
lying results had been excluded before the statistical
evaluation was performed. Six of the ten excluded
ciclosporin results belonged to specimens from renal-,
four to specimens from heart-transplant recipients.
None of the 10 patients had disturbed liver function
or any indication of an accumulation of ciclosporin
metabolites. Repeated analysis in these ten specimens
did not confirm the ciclosporin values of the original
analysis. Outliers were not mentioned in any other
publication on the evaluation of the EMIT ciclosporin
assay. Other reasons than non-specificity appeared to
be responsible for the observed unacceptable inaccu-
racy. We observed that the sample pretreatment of
EMIT occasionally may cause grossly false positive
ciclosporin measurements. The source of the observed
inadequate accuracy is probably located in the protein
precipitation step, and/or the centrifugation proce-
dure. The principle of EMIT limits the selection of
highly effective precipitating agents. Heavy metal salts
(CuSO4 or ZnSO4) cannot be used because these re-
agents would deactivate the indicator enzyme glucose-
6-phosphate dehydrogenase. It was to be expected
that a mixture of sample and methanol (1 volume to
2 volumes) would not form a solid pellet of precipi-
tated proteins after centrifugation. The protein pellet
tended to release floating particles. We supposed that
in some samples turbidity, even though not visible to
the eye, was the explanation for poorly reproducible
and incorrect results. We obtained satisfactory accu-
racy and reproducibility when the supernatant was
centrifuged twice. Alternatively, the use of a larger
sample volume for the sample pretreatment seemed
to be similarly effective, and less labour-intensive.
Both modifications required very careful handling of
the sample cups after centrifugation, and during up-
take of the supernatant. The results of our method
comparison Study II comparing two modifications of
sample pretreatment ('EMIT vs 2EMIT) showed that
both sample pretreatment procedures were able to
effectively avoid outlying measurements. Different
Eur. J. din. Chem. Clin. Biochera. / Vol. 31,1993 / No. 6
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calibration modes had no influence on the results of
Study II with samples from patients. However, our
studies of the precision of EMIT indicated.that cali-
bration and ciclosporin measurements by use of the
2-point mode were able to improve the assay preci-
sion, especially for the determination of ciclosporin
concentrations below 100 μ§/1. This finding might be
of use if ciclosporin monitoring in a low concentration
range is required. At present we recommend 2-point
calibration to achieve a lower imprecision of measure-
ment by EMIT. Correctly, Syva's recommendation to
users of the assay is to prolong the measuring time
from 350 s to 550 s and to record eleven signals in-
stead of four [personal communication from Syva,
Darmstadt, Germany]. The random variation of the
determined mean absorbance difference averaged over
11 intervals should be lower. Consequently, an im-
proved assay precision should be obtainable by means
of this modified measuring design.
In conclusion, the EMIT™ cyclosporine assay pro-
vides highly specific measurements of ciclosporin in
whole blood. The precision of the EMIT at ciclosporin
concentrations > 100 μg/l is adequate. For improved
precision of ciclosporin concentration measurements
below 100 μg/l the assay should be performed using
the described 2-point measuring design. Ciclosporin
analysis can be completed after 1—2 hours. The ac-
curacy of the assay depends on skilful analytical per-
formance by well-trained personnel. However, re-
peated analysis may be necessary if the plausibility of
ciclosporin measurement in a follow-up of ciclosporin
monitoring is questionable. The EMIT assay is well
suited for regular ciclosporin monitoring.
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